Silexion Therapeutics Ltd. (SLXNW) Stock Overview
Explore Silexion Therapeutics Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Silexion Therapeutics Ltd. (SLXNW)
Key Financials
Key Financials
Market Cap
13.5K
P/E Ratio
0.03
EPS (TTM)
$-39.55
ROE
-5.17%
SLXNW Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Silexion Therapeutics Ltd. (NASDAQ: SLXNW) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Silexion Therapeutics Ltd.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of SLXNW on the NASDAQ shows an RSI of 46.56, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.
Key metrics behind Silexion Therapeutics Ltd.'s NASDAQ-traded stock include a P/E ratio of 0.03 and a market capitalization of 13.5K. Combined with our AI analysis, these give both institutional and retail investors a clear view of SLXNW on the NASDAQ.